However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
I.MazokopakisE
Crucially, comprehensive drug safety testing in mice indicated no significant adverse effects on myocardial, liver, or renal function markers after 30 days of treatment, suggesting a favorable safety profile [2]
For instance, using multiple different types of GHRPs at once is often less effective than a well-timed protocol with one
At the growth-factor level, BPC-157 modulates expression of EGF (epidermal growth factor), FGF (fibroblast growth factor), and TGF-beta in injured tissue, coordinating a multi-pathway repair response that few single-agent peptides can match
